Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to sign a written consent form for the trial
- People who are 18 years of age or older at the time of signing the consent form
- People who have a confirmed diagnosis of melanoma with at least two in-transit lesions (small tumours that have spread from the original site but are still in the skin or nearby tissue) at different distances from the original tumour site, or who have been identified as having this type of spread by a melanoma specialist
- People with cutaneous (skin), mucosal (lining of body cavities), or uveal (eye) melanoma
- People who are currently receiving treatment for melanoma, as well as those who have not yet had any treatment
- Women who could become pregnant must have a negative pregnancy test (urine or blood) within 7 days before receiving a study-related substance called pimonidazole
Who may not be able to join:
- People whose in-transit lesions cannot be safely biopsied (sampled with a needle or small procedure), as determined by their treating doctor
- People who have a known ongoing condition that significantly suppresses their immune system, including those taking certain medications such as Remicade, mycophenolate, methotrexate, or prednisone at doses greater than 20 mg per day
- People who are known to be HIV positive, or positive for Hepatitis B or Hepatitis C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yana Najjar, MD, UPMC Hillman Cancer Center
Phone: 412-623-1191
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Immunometabolic profiling; Tumor cell metabolism; Imaging of individual ITM stations; hypoxia exposure analyses
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.